- Home
- RCS vs TRVI Comparison
RCS vs TRVI Comparison
Compare RCS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- TRVI
- Stock Information
- Founded
- RCS 1994
- TRVI 2011
- Country
- RCS United States
- TRVI United States
- Employees
- RCS N/A
- TRVI N/A
- Industry
- RCS Investment Managers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- TRVI Health Care
- Exchange
- RCS Nasdaq
- TRVI Nasdaq
- Market Cap
- RCS 292.8M
- TRVI 341.4M
- IPO Year
- RCS N/A
- TRVI 2019
- Fundamental
- Price
- RCS $6.54
- TRVI $3.56
- Analyst Decision
- RCS
- TRVI Strong Buy
- Analyst Count
- RCS 0
- TRVI 8
- Target Price
- RCS N/A
- TRVI $9.31
- AVG Volume (30 Days)
- RCS 141.1K
- TRVI 659.4K
- Earning Date
- RCS 01-01-0001
- TRVI 03-19-2025
- Dividend Yield
- RCS 10.12%
- TRVI N/A
- EPS Growth
- RCS N/A
- TRVI N/A
- EPS
- RCS N/A
- TRVI N/A
- Revenue
- RCS N/A
- TRVI N/A
- Revenue This Year
- RCS N/A
- TRVI N/A
- Revenue Next Year
- RCS N/A
- TRVI N/A
- P/E Ratio
- RCS N/A
- TRVI N/A
- Revenue Growth
- RCS N/A
- TRVI N/A
- 52 Week Low
- RCS $4.51
- TRVI $1.30
- 52 Week High
- RCS $6.31
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- RCS 41.39
- TRVI 43.13
- Support Level
- RCS $6.26
- TRVI $3.63
- Resistance Level
- RCS $6.50
- TRVI $4.06
- Average True Range (ATR)
- RCS 0.32
- TRVI 0.30
- MACD
- RCS 0.01
- TRVI -0.11
- Stochastic Oscillator
- RCS 41.35
- TRVI 0.44
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.